Sfondo Header
L'angolo del dottorino
Search the site... Advanced search
✖

Cardiac metastases

Cardiac metastases are deposits of an extracardiac neoplasm within heart tissue. They may infiltrate the myocardium, reach the endocardium, protrude into the chambers, or involve several compartments simultaneously. Their biological identity remains that of the primary tumor: a myocardial melanoma metastasis retains diagnostic characteristics and treatment sensitivities different from those of breast carcinoma or lymphoma. Cardiac involvement adds particular functional vulnerability, because relatively localized lesions may interfere with electrical conduction, cardiac filling, or blood ejection.

In clinical practice, the term is sometimes used to describe all secondary neoplastic involvement of the heart. A precise description distinguishes metastatic dissemination from direct contiguous invasion by a thoracic tumor and from endovascular growth reaching the atria through the great veins. These pathways may yield similar imaging appearances but have different implications for staging, resectability, and treatment. Pericardial metastases represent another common manifestation of cardiopericardial spread, often dominated by effusion; myocardial and intracavitary deposits instead make mural infiltration, obstruction, and arrhythmic or embolic events particularly relevant.

Origin and epidemiology

Secondary involvement is overall more common than primary cardiac tumors. Its frequency, however, varies substantially with the population studied: autopsies of patients with disseminated neoplasms also detect microscopic deposits and terminal disease, whereas clinical series chiefly include lesions visible on imaging or responsible for symptoms. These data measure different phenomena and cannot yield a single probability of cardiac metastasis applicable to every person with cancer. Improved cancer survival and greater availability of cardiac imaging also alter opportunities for diagnosis, without in themselves proving increased biological tropism of tumors for the heart.

The neoplasms most frequently represented include lung carcinomas, breast carcinoma, melanoma, and hematologic neoplasms. Sarcomas, renal carcinomas, and numerous gastrointestinal or other organ tumors may also metastasize to the heart. Melanoma has a recognized propensity to involve the myocardium, especially in disseminated disease; the numerical predominance of lung carcinomas also reflects their high prevalence and anatomical proximity. Rankings derived from individual series therefore depend on the spectrum of tumors treated and on the methods used to detect cardiac involvement.

The disease may emerge during already documented systemic progression, be discovered incidentally during radiologic reassessment, or, less often, be the first manifestation of a previously unknown neoplasm. A long interval after treatment of the primary tumor does not exclude recurrence, but makes comparison with previous histology and imaging particularly important. The oncologic history changes the diagnostic probability; it does not automatically make every cardiac mass a metastasis, because thrombi, vegetations, primary tumors, and anatomical variants remain possible.

Routes of spread and pathological anatomy

In hematogenous dissemination, tumor cells or neoplastic aggregates reach the cardiac microcirculation, cross the vascular wall, and establish intramyocardial deposits. Whether a deposit develops depends on tumor properties, its ability to survive in the circulation, and interactions with host tissue. Lymphatic spread, often associated with mediastinal disease, may involve the epicardium and superficial myocardium, sometimes together with the pericardium. Lymphatic obstruction and disrupted drainage favor an infiltrative distribution that may be inconspicuous as a discrete mass.

Direct extension from a pulmonary or mediastinal malignancy progresses through adjacent tissue planes. Growth along a vein may instead reach the right atrium through the vena cava, as occurs in certain renal or hepatic tumors, or the left atrium through the pulmonary veins. In such circumstances, demonstrating vascular continuity changes interpretation: an intraluminal column of tumor is not necessarily equivalent to a distant myocardial deposit. A blood clot may also form around or downstream from tumor tissue, creating a mixed lesion in which the neoplastic component, thrombotic component, and infiltrated wall must be distinguished.

Macroscopically, metastases may appear as multiple nodules, a dominant mass, segmental wall thickening, or diffuse infiltration. Endocardial and valvular deposits are less common than pericardial and myocardial involvement. Growth toward a chamber exposes neoplastic tissue to blood-flow forces and may promote surface thrombosis, fragmentation, or obstruction. Necrosis, hemorrhage, and heterogeneous vascularity contribute to radiologic heterogeneity; finding avascular areas within a mass does not mean the entire lesion is a thrombus.

On microscopy, a metastasis reproduces the characteristics of the primary tumor, although grade and differentiation may differ. Classification requires integration of morphology, immunohistochemistry, and clinical information. Marker panels are selected to distinguish epithelial, melanocytic, lymphoid, or mesenchymal lineages and subsequently narrow the likely site of origin. A single marker rarely settles a complex case. Comparison with primary-tumor tissue and assessment of pertinent molecular alterations help distinguish recurrence from a second neoplasm and preserve information relevant to treatment.

Myocardial, electrical, and hemodynamic consequences

Infiltration replaces or compresses cardiomyocytes and alters interstitial architecture. This may cause changes in contractility, reduced compliance, and regional or global dysfunction. Ejection fraction may remain preserved even when filling is impaired or a wall is extensively infiltrated. Functional damage depends on extent, growth rate, site, and pre-existing heart disease; anemia, infections, pulmonary embolism, and treatment toxicity may contribute simultaneously to dyspnea and low cardiac output.

Involvement of the septum, atrioventricular node, or conduction pathways may cause atrioventricular block and intraventricular conduction disturbances. Infiltration, edema, local ischemia, and heterogeneous conduction form a substrate for premature beats and atrial or ventricular tachyarrhythmias. A lesion near an electrically critical structure may have consequences disproportionate to its volume. Absence of symptoms at diagnosis therefore does not alone indicate low risk, particularly when ECG and imaging demonstrate progressive septal involvement.

Intracavitary masses may impede venous inflow, functionally cross a valve orifice, or narrow an outflow tract. Obstruction also depends on mobility, its relationship to the cardiac cycle, and loading conditions. Infiltration of valvular or subvalvular structures may cause regurgitation; involvement of the venae cavae produces systemic congestion or vena cava syndrome, whereas pulmonary vein involvement may contribute to pulmonary congestion. Doppler links anatomical findings to their effect on blood flow, avoiding interpretation of size alone as a measure of severity.

Embolization may result from tumor fragments or thrombotic material attached to the lesion. A right-sided mass may affect the pulmonary circulation; a left-sided lesion may cause systemic events, including cerebral events. In patients with cancer, however, thromboembolism unrelated to the cardiac mass is also common: causal attribution requires consideration of venous thromboses, catheters, arrhythmias, and other possible sources. Less commonly, coronary infiltration or compression and microembolization may cause ischemia. The presence of a neoplasm does not justify attributing acute chest pain to the metastasis before common cardiovascular emergencies have been evaluated.

Clinical manifestations, history, and physical examination

Some deposits are asymptomatic and are identified during investigations for the underlying neoplasm. In symptomatic cases, dyspnea, fatigue, reduced exercise tolerance, palpitations, and chest pain predominate, but these symptoms are poorly specific in oncology. Syncope, presyncope, or bradycardia suggest conduction abnormalities or hemodynamically important obstruction; persistent tachycardia may reflect arrhythmia, anemia, infection, embolism, or compensation for low output. The pattern of onset and change from baseline are often more informative than any individual symptom.

The history establishes histologic type, stage, metastatic sites, response to treatment, and therapies received, including thoracic radiotherapy, cardiotoxic drugs, and immunotherapy. Central venous access, previous thromboembolism, recent infections, and antithrombotic treatment must also be documented. Comparing new symptoms with treatment timing helps assess cardiovascular toxicity, treatment-associated myocarditis or pericarditis, without assuming that mere temporal coincidence proves the mechanism. Isolated cardiac progression deserves particular attention when other sites are responding.

Physical examination looks for signs of congestion, hypoperfusion, irregular pulse, new murmurs, and changes in jugular venous pressure. Edema, hepatomegaly, and ascites suggest elevated right-sided pressures but may also have hepatic, renal, or nutritional causes. A murmur may indicate interference with a valve, whereas the absence of auscultatory findings does not exclude extensive infiltration. Hypotension, altered mental status, cold extremities, or sustained arrhythmia require urgent evaluation of cardiac function and reversible causes before oncologic characterization is completed.

Initial investigations and echocardiography

The electrocardiogram may show new repolarization changes, Q waves, conduction disturbances, or arrhythmias, but no ECG pattern is diagnostic of metastasis. Persistent ST-segment changes may accompany myocardial infiltration and mimic an acute coronary syndrome; distinction depends on the clinical picture, biomarker trends, and imaging. Rhythm monitoring is indicated according to symptoms and electrical risk. Troponin and natriuretic peptides indicate myocardial injury and wall stress, respectively, without identifying their cause; blood counts, renal function, electrolytes, and liver tests help identify concurrent factors and plan care.

Transthoracic echocardiography is usually the first targeted investigation. It should document the lesions' location, number, size, attachment, and mobility, together with biventricular function, valves, estimated pressures, and pericardium. Doppler quantifies obstructive effects and regurgitation; careful examination also searches for small effusions or regional abnormalities in walls that appear free of a mass. Echocardiographic contrast agents may improve endocardial border definition and, in appropriate settings, provide information about lesion perfusion. Their interpretation remains part of a multimodal assessment.

Transesophageal echocardiography is useful when transthoracic windows are inadequate or additional detail is needed about the atria, septum, valves, pulmonary veins, or caval junctions. It provides important information for procedures and surgery but does not automatically replace magnetic resonance imaging for tissue characterization. Selection accounts for respiratory condition, sedation needs, and possible esophageal contraindications. In an unstable patient, the most useful examination is the one that promptly clarifies the mechanism of instability and enables treatment.

MRI, CT, PET, and differential diagnosis

Cardiac magnetic resonance imaging combines cine sequences, T1 and T2 tissue characterization, perfusion, and late contrast enhancement. It determines whether a lesion is intramural or intracavitary, how much myocardium it involves, and its relationship to adjacent structures. Metastases show variable signals depending on cellularity, water, hemorrhage, fat, and necrosis; vascularization may be homogeneous or patchy. Some melanotic melanoma deposits are hyperintense on T1, but amelanotic melanomas and hemorrhages from other causes limit the diagnostic value of this isolated feature. The protocol must be adapted to the clinical question and patient tolerance.

Distinction from an intracardiac thrombus is particularly important. A thrombus generally lacks perfusion and substantial enhancement, whereas viable tumor tissue tends to enhance; however, organized thrombi with more complex features, extensively necrotic tumors, and mixed masses do occur. Location, relationship to catheters or akinetic segments, dedicated sequences, and changes over time improve accuracy. Brief observation during anticoagulation may be reasonable in selected cases with strong suspicion of thrombus, but must not delay a necessary diagnosis in the presence of obstruction, progressive infiltration, or high embolic risk.

Contrast-enhanced CT is especially useful for demonstrating continuity with thoracic tumors, extension into the venae cavae or pulmonary veins, relationships with coronary arteries and mediastinum, calcifications, and associated lung disease. A filling defect on a non-ECG-gated scan or one acquired at an unsuitable phase may result from blood mixing and require dedicated confirmation. Choosing between CT and MRI involves the clinical question, stability, renal function, devices, claustrophobia, and expected image quality. Complementary information may be needed without requiring every imaging modality in every patient.

PET/CT mainly contributes to staging and evaluation of metabolically active disease in histologic types for which it is appropriate. Physiologic myocardial FDG uptake may mask or mimic lesions, so a cardiac question requires appropriate preparation and interpretation. High uptake may also occur with infection or inflammation, while a small, necrotic, or poorly avid lesion may be barely visible. PET does not replace histology when this determines treatment choice, nor does it alone quantify the risk of obstruction or conduction block.

The differential diagnosis includes primary tumors, infectious or nonbacterial thrombotic vegetations, anatomical pseudomasses, and device- or procedure-related changes. A valve vegetation in a patient with cancer warrants microbiologic and clinical evaluation, because nonbacterial thrombotic and infective endocarditis require different strategies. A cardiac myxoma may also be discovered during follow-up for an extracardiac neoplasm. Metastasis becomes more likely with infiltration, multiplicity, and concordance with cancer progression, but no single imaging sign makes clinical integration unnecessary.

Diagnostic confirmation and assessment of extent

The need for a biopsy should be assessed by identifying which decision depends on its result. In an already characterized neoplasm with concordant dissemination and a typical cardiac finding, the risks of sampling the heart may exceed the benefit. If cardiac involvement is isolated, discordant with changes elsewhere, or compatible with a different treatable tumor, tissue confirmation becomes more important. When histology or profiling requires material, a representative and more accessible extracardiac site should be sought first. However, a sample from a discordant site may not resolve the specific question about the cardiac mass.

Endomyocardial, transvenous, percutaneous, or surgical sampling is planned at an experienced center, considering bleeding risk, perforation, embolization, proximity to coronary arteries, and the need to obtain viable tissue. A friable left-sided or highly vascularized mass poses different problems from right-sided infiltration accessible under imaging guidance. Necrotic areas may yield nondiagnostic specimens; the quantity and handling of material must allow the intended investigations. If a lymphoid neoplasm is suspected, planning sample allocation for immunophenotyping and appropriate analyses in advance avoids losing essential information.

An associated effusion may provide material for cytology and a cell block, potentially supplemented by flow cytometry. Malignant cells document neoplastic involvement of the pericardial compartment but do not automatically establish the nature of every other lesion seen in the heart. Negative cytology does not exclude infiltration without cellular shedding into the fluid. Interpretation must therefore keep information from fluid, the mass, and extracardiac tissues separate.

Staging follows the classification system for the primary tumor and includes extracardiac investigations relevant to that histologic type, including neurologic assessment when indicated. Distant metastasis, local invasion, and venous extension do not necessarily receive the same classification. In parallel, an operational cardiovascular map is needed: lesion number and site, residual wall thickness, relationship to valves and vessels, ventricular function, electrical risk, pericardium, and presence of thrombosis. No single cardiac stage is valid for all these neoplasms.

Pretreatment assessment integrates performance status, frailty, renal and hepatic reserve, comorbidities, prior cardiotoxic exposures, and the person's goals. Multidisciplinary discussion among oncology, cardiology, imaging, pathology, cardiac surgery, and radiation oncology should clarify both local urgency and the prospects for controlling systemic disease. A patient with an obstructive lesion and treatment-sensitive tumor has a different benefit-risk balance from someone with refractory multiorgan progression and limited physiologic reserve.

Cancer treatment and local control

Systemic therapy is often the cornerstone of treatment because cardiac deposits accompany disease at other sites. Selection depends on histology, biomarkers, prior therapies, and likelihood of response, not merely on the metastasis's location. In breast carcinoma, hormone receptors and HER2 are relevant; in lung carcinoma, actionable molecular alterations and immunobiological characteristics may guide treatment; in melanoma, molecular profile and indications for immunotherapy are among the pertinent factors. Regimens must be appropriate for each neoplasm, with adjustments required by the cardiovascular condition.

Deposits from systemic lymphoma follow hematologic classification and treatment principles. Some histologic subtypes can regress rapidly and profoundly even when imaging shows substantial cardiac infiltration. This sensitivity makes it essential to avoid delaying effective therapy through extensive resection, but also calls for monitoring at treatment initiation: electrolyte disturbances from tumor lysis, changes in the infiltrated wall, and rhythm instability may complicate response. Management of secondary lymphoma differs from that of primary cardiac lymphoma, despite sharing several cardiologic challenges.

Myocardial metastases call for assessment of cardiotoxicity risk and oncologic alternatives. ECG, ventricular function, and biomarkers are used according to the drug, clinical situation, and risk, without treating every cardiac finding as an absolute contraindication to cancer therapy. If deterioration occurs during treatment, progression, toxicity, thromboembolism, infection, and other treatable causes must be distinguished. The benefit of active anticancer treatment may be substantial even when the drug requires intensified monitoring.

Surgery is reserved for selected circumstances: a limited technically resectable lesion, controlled primary cancer, a prospect of lasting benefit, or obstruction or mechanical risk that precludes waiting for a drug response. Its purpose may exceptionally be radical, or it may be diagnostic or palliative. Decisions consider intramural extent, need for wall or valve reconstruction, extracardiac disease, postoperative recovery, and delays to systemic treatment. Selected surgical series do not prove that resection improves survival in all patients with cardiac metastases.

Radiotherapy may be considered for local control or symptom relief when anatomy, radiosensitivity, and prior treatment permit. Planning must account for cardiac and respiratory motion, target volume, and dose to healthy structures, including coronary arteries and the conduction system. Conformal and stereotactic techniques offer options in selected cases, but evidence specifically concerning intracardiac metastases remains limited and does not establish a universal regimen. Expected benefit, time to response, and toxicity risk must be weighed against available alternatives.

Treatment of cardiovascular consequences

Heart failure is treated according to phenotype, blood pressure, renal function, and the predominant mechanism. Diuretics may relieve congestion, but critical obstruction or marked preload dependence requires caution with volume removal. Treatments for ventricular dysfunction must be integrated with treatment of the mass and overall tolerability. Dyspnea and fatigue may persist for extracardiac reasons even after a good local response, so clinical goals must be measured directly.

Arrhythmias require correction of precipitating factors and management consistent with hemodynamic stability and heart disease. Symptomatic advanced conduction block may require pacing support; the definitive strategy considers possible regression of infiltration, infection, vascular access, and the oncologic course. Choosing devices to prevent arrhythmic death likewise depends on anticipated clinical benefit, reversibility of the substrate, and patient preferences. Interactions between antiarrhythmics, anticancer drugs, and QT-prolonging medicines must be assessed explicitly.

Anticoagulation is indicated when a thrombotic component or another appropriate clinical indication exists, such as venous thromboembolism or atrial fibrillation with a favorable benefit-risk balance. It does not dissolve metastatic tissue or provide proven protection against every tumor embolus. Drug selection considers bleeding, thrombocytopenia, renal function, interactions, tumor sites, and planned procedures. In a mixed mass, a reduction in thrombus may improve imaging appearance without representing an oncologic response; conversely, a persistent mass alone does not prove anticoagulation failure.

Control of pain, dyspnea, and anxiety, nutritional support, and integrated palliative care accompany active treatment. When a procedure is unlikely to improve symptoms or independence, its burden may outweigh the expected benefit. This assessment must be based on individual circumstances and shared goals, not on an automatic assumption associated with the word metastasis. Even a purely symptomatic intervention may be valuable if it reduces hospital admissions or enables continuation of effective therapy.

Response assessment and prognosis

Follow-up must assess oncologic response and cardiovascular safety separately. Lesion size, metabolic activity, and tissue characteristics are compared with previous studies obtained as consistently as possible; flow, ventricular function, valves, rhythm, and symptoms are assessed in parallel. A modest size reduction may be clinically important if it relieves obstruction, while a stable mass may become dangerous if its mobility changes or it involves conduction tissue. Residual fibrosis, necrosis, and thrombus need interpretation before being labeled progression.

Monitoring frequency depends on local risk, disease pace, and treatment. Septal lesions with electrical abnormalities, mobile masses, or obstructions require closer surveillance than a small, stable, silent deposit. New symptoms warrant early reassessment even if the planned oncologic review is distant. Multidisciplinary reassessment is particularly useful for discordant responses when extracardiac disease shrinks but the cardiac mass persists or grows.

Prognosis is often determined by disseminated cancer but varies with histologic type, treatment sensitivity, extracardiac burden, and functional consequences. In an observational study of 112 patients with cardiac metastases identified by MRI and matched oncologic controls, cardiac involvement was associated with worse outcomes; heterogeneous enhancement with poorly vascularized components provided additional prognostic information. These findings relate anatomy to biology but are not a validated score to determine an individual patient's therapy on their own. Median outcomes from case series should not replace an individualized prognosis updated according to response and available options.

Complications

Major complications include low cardiac output, refractory congestion, valvular or vascular obstruction, valve regurgitation, sustained arrhythmias, conduction block, and embolization. Ischemia may result from coronary involvement or coexist because of independent coronary artery disease. Pericardial extension may add tamponade or constriction; very advanced infiltration may compromise wall integrity, although rupture is rare. Several mechanisms may contribute to the same deterioration, making prompt, physiology-directed assessment essential.

The effects of treatment compound those of the tumor: bleeding during anticoagulation or procedures, infections, perforation, surgical complications, myocardial toxicity, and metabolic disturbances during a rapid response. Prevention requires coordinated planning of procedures, antithrombotic management, and monitoring. Recognizing local risk early may sometimes allow anticancer treatment to continue; when disease progresses despite therapy, symptom control and proportionality of interventions remain central clinical goals.

Bibliography
  1. Bussani R et al. Cardiac metastases. Journal of Clinical Pathology. 2007;60(1):27-34.
  2. Tyebally S et al. Cardiac Tumors: JACC CardioOncology State-of-the-Art Review. JACC: CardioOncology. 2020;2(2):293-311.
  3. Basso C et al. Cardiac masses and tumours. Heart. 2016;102(15):1230-1245.
  4. Angeli F et al. Multimodality Imaging in the Diagnostic Work-Up of Patients With Cardiac Masses: JACC: CardioOncology State-of-the-Art Review. JACC: CardioOncology. 2024;6(6):847-862.
  5. Mousavi N et al. Assessment of Cardiac Masses by Cardiac Magnetic Resonance Imaging: Histological Correlation and Clinical Outcomes. Journal of the American Heart Association. 2019;8(1):e007829.
  6. Shenoy C et al. Cardiovascular magnetic resonance imaging in suspected cardiac tumour: a multicentre outcomes study. European Heart Journal. 2022;43(1):71-80.
  7. Chan AT et al. Risk stratification of cardiac metastases using late gadolinium enhancement cardiovascular magnetic resonance: prognostic impact of hypo-enhancement evidenced tumor avascularity. Journal of Cardiovascular Magnetic Resonance. 2021;23:42.
  8. Lyon AR et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European Heart Journal. 2022;43(41):4229-4361.
  9. Mori S et al. Pericardial effusion in oncological patients: current knowledge and principles of management. Cardio-Oncology. 2024;10:8.
  10. Takeda K et al. Higher sensitivity of pericardial fluid cytology than biopsy in malignant effusions with potential explanation of false-negative cytology: A multi-institutional analysis. Cytopathology. 2025;36(1):31-40.
  11. Thieblemont C et al. Large B-cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up. HemaSphere. 2025;9(9):e70207.

Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.

Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.